BDX Stock Recent News

Becton, Dickinson and Company (NYSE:BDX ) Bank of America Securities Health Care Conference Call May 13, 2025 1:00 PM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Conference Call Participants Travis Steed - Bank of America Securities Travis Steed [Starts Abruptly] I'm Travis Steed, Medical Device Analyst at Bank of America and I'm fortunate to have Tom Polen up next, CEO at Becton, Dickinson. So welcome.

FRANKLIN LAKES, N.J. , May 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kings, including Altria and Canadian Utilities, are now fairly priced, with annual dividends from $1K investments exceeding their single-share prices. Analysts predict net gains of 14.7% to 56.86% for the top ten Dividend Kings by yield for the coming year, based on target prices. Among the 55 Dividend Kings, 16 show negative free cash flow margins, making them cash-poor and unsafe for investment.

Becton Dickinson, and Company BDX lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.

I'm going on a 2-week vacation with my family for my sister's wedding, so I've prepared a comprehensive article with three types of dividend aristocrat recommendations for whateveriscomingnext. Low-volatility aristocrats offer a 3.4% yield, a 46% downside capture ratio, and 52% less volatility than the S&P, making them ideal for addressing recession concerns while still providing a 23% return. High-yield aristocrats offer a 7% average yield with 11%-12% long-term return potential, providing low-risk income regardless of market or economic conditions.

Becton Dickinson & Co.'s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its research instrument sales.

Becton, Dickinson and Company (NYSE:BDX ) Q2 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Mike Garrison - President of the Medical Mike Feld - President of the Life Sciences Rick Byrd - President of the Interventional Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Matt Taylor - Jefferies Travis Steed - Bank of America Patrick Wood - Morgan Stanley David Roman - Goldman Sachs Matt Miksic - Barclays Operator Hello, and welcome to BD's Second Fiscal Quarter 2025 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-2385 for domestic calls and area code +1-402-220-7203 for international calls.

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CNBC's Jim Cramer explains why he is keeping an eye on shares of Becton Dickinson.

Becton Dickinson (BDX) came out with quarterly earnings of $3.35 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.17 per share a year ago.